Effects on hemostatic variables of desogestrel- and gestodene- containing oral contraceptives in comparison with levonorgestrel-containing oral contraceptives: A review

American Journal of Obstetrics and Gynecology

Volumn 179, Issue 3 II, 1998, Pages

  Winkler, U H ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Activated protein C sensitivity ratio; Factor VII; Hemostasis; Oral contraceptives; Venous thromboembolism

Indexed keywords

DESOGESTREL; ETHINYLESTRADIOL; GESTODENE; LEVONORGESTREL; NORGESTIMATE;

ARTICLE; DRUG FORMULATION; DRUG SAFETY; FEMALE; HEMOSTASIS; HORMONAL CONTRACEPTION; HUMAN; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOEMBOLISM; THROMBOGENESIS;

EID: 0031686875     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1053/ob.1998.v179.a92633     Document Type: Article

References (74)

1. World Health Organization World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception: Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease Lancet 346 1995 1582 1588
2. H Jick SS Jick V Gurewich MW Myers C. Vasilakis Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing pro-gestagen components Lancet 346 1995 1589 1593
3. WO Spitzer MA Lewis LA Heinemann M Thorogood KD. MacRae Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study BMJ 312 1996 83 88
4. RD Farmer RA Lawrenson CR Thompson JG Kennedy IR. Hambleton Population-based study of risk of venous thromboembolism associated with various oral contraceptives Lancet 349 1997 83 88
5. B Edström Ø Lidegaard Venous thromboembolism and oral contraceptives: a case-control study Acta Obstet Gynecol Scand 76 suppl 167 1997 23
6. S Suissa L Blais WO Spitzer J Cusson M Lewis L. Heinemann First-time use of newer oral contraceptives and the risk of venous thromboembolism Contraception 56 1997 141 146
7. Ø Lidegaard I. Milsom The pill: the controversy continues Acta Obstet Gynecol Scand 75 1996 93 97
8. C Kluft M. Lansink Effect of oral contraceptives on haemostasis variables Thromb Haemost 78 1997 315 326
9. GB Melis F Fruzzetti I Nicoletti C Ricci P Lammers WJ Atsma A comparative study on the effects of a monophasic pill containing desogestrel plus 20 mg ethinylestradiol, a triphasic combination containing levonorgestrel and a monophasic combination containing gestodene on coagulatory factors Contraception 43 1991 23 31
10. CR Sirtori L Calabresi G Franceschini G Gianfranceschi F Zoppi S Winkler Comparison of the lipoprotein and hemostatic changes after a triphasic and a monophasic low dose oral contraceptive in premenopausal middle-aged women Atherosclerosis 84 1990 203 211
11. IH Omsjö P Oian JM Maltau B. Osterud Effects of two triphasic oral contraceptives containing ethinylestradiol plus levonorgestrel or gestodene on blood coagulation and fibrinolysis Acta Obstet Gynecol Scand 68 1989 27 30
12. RN Prasad S Koh SS. Ratnam Effects of three types of combined O.C. pills on blood coagulation, fibrinolysis and platelet function Contraception 39 1989 369 383
13. M Vekemans J Grippa P Capel P. Fondu The effect of two low-dose contraceptives containing ethinylestradiol and desogestrel or d-norgestrel on blood clotting factors Curr Ther Res 42 1987 1109 1118
14. R Gramolini G Perrone E Calzolari M Manlone A Maasci P Materazzi Assessment of certain coagulation tests in women taking low-dose oral contraceptives Pathologia e Clinica Obstetrica e Ginecologica 15 1987 307 312
15. I Rakoczi G Gero J Demeter I. Gati Comparative metabolic effects of oral contraceptive preparations containing different progestagens: effects of desogestrel + ethinylestradiol on the haemostatic balance Arzneimittelforschung 35 1985 630 633
16. HJ Kloosterboer RG van Wayjen A. van den Ende Effects of three low-dose oral contraceptive combinations on sex hormone binding globulin, corticosteroid binding globulin and antithrombin III activity in healthy women: two monophasic desogestrel combinations (containing 0.020 or 0.030 mg ethinylestradiol) and one triphasic levonorgestrel combination Acta Obstet Gynecol Scand 144 1987 41 44 [suppl]
17. A Kjaer AM Lebech B Borggaard H Refn LR Pedersen L Schierup Lipid metabolism and coagulation of two contraceptives: correlation to serum concentrations of levonorgestrel and gestodene Contraception 40 1989 665 673
18. J Bonnar L Daly E. Carroll Blood coagulation with a combination pill containing gestodene and ethinyl estradiol Int J Fertil 32 1987 21 28 (suppl)
19. H Refn A Kjaer AM Lebech B Borggaard L Schierup A. Bremmelgaard Metabolic changes during treatment with two different progestogens Am J Obstet Gynecol 163 1990 374 377
20. KF Weinges E Wenzel P Hellstern TB Geurts TO. Dieben The effects of two phasic oral contraceptives on hemostasis and platelet function Adv Contracept 11 1995 227 237
21. MJ Ball E Ashwell M Jackson MD. Gillmer Comparison of two triphasic contraceptives with different progestogens: effects on metabolism and coagulation proteins Contraception 41 1990 363 376
22. H Cohen IJ Mackie K Walshe MD Gillmer SJ. Machin A comparison of the effects of two triphasic oral contraceptives on haemostasis Br J Haematol 69 1988 259 263
23. CH Nielsen HK Poulsen B Teisner P Thorsen J Hau JG. Westergaard Changes in blood levels of proteinase inhibitors, pregnancy zone proteins, steroid carriers and complement factors induced by oral contraceptives Eur J Obstet Gynecol Reprod Biol 51 1993 63 71
24. UH Winkler C Oberhoff U Bier AE Schindler D. Gillain Hemostatic effects of two oral contraceptives containing low doses of ethinyl estradiol and either gestodene or norgestimate: an open randomized, parallel-group study Int J Fertil 40 1995 260 268
25. P Quehenberger U Loner S Kapiotis S Handler B Schneider J Huber Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives Thromb Haemost 76 1996 729 734
26. KA Bauer RD. Rosenberg The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation Blood 70 1987 343 350
27. H Pelzer A Schwarz W. Stüber Determination of human prothrombin activation fragment 1 + 2 in plasma with an antibody against a synthetic peptide Thromb Haemost 65 1991 153 159
28. KA. Bauer Inherited hypercoagulable states J Loscalzo AI Schafer Thrombosis and hemorrhage 1994 Blackwell Scientific Boston 809 834
29. PM Mannucci A Tripodi B Bottasso F Baudo G Finazzi V De Stefano Markers of procoagulant imbalance in patients with inherited thrombophilic syndromes Thromb Haemost 67 1992 200 202
30. LH Lee I Jennings R Luddington T. Baglin Markers of thrombin and plasmin generation in patients with inherited thrombophilia J Clin Pathol 47 1994 631 634
31. TW Meade S Mellows M Brozovic GJ Miller RR Chakrabarti WR North Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study Lancet 2 1986 533 537
32. Consensus Development Meeting: metabolic aspects of oral contraceptives of relevance for cardiovascular diseases Am J Obstet Gynecol 162 1990 1335 1337
33. PR Eisenberg LA Sherman J Perez AS. Jaffe Relationship between elevated plasma levels of crosslinked fibrin degradation products (XL-FDP) and the clinical presentation of patients with myocardial infarction Thromb Res 46 1987 109 120
34. MF Lopez Fernandez J Battle R Solar M. Marini Diaz Markers of haemostatic system activation in 80 patients with deep venous thrombosis submitted to fibrinolytic therapy Fibrinolysis 9 1995 231 236
35. The DVTENOX Study Group Markers of hemostatic system activation in acute deep venous thrombosis: evolution during the first days of heparin treatment Thromb Haemost 70 1993 904 909
36. JS Ginsberg P Brill-Edwards A Panju A Patel J McGinnis F Smith Pre-operative plasma levels of thrombin–antithrombin III complexes correlate with the development of venous thrombosis after major hip or knee surgery Thromb Haemost 74 1995 602 605
37. LN Jorgensen B Lind O Hauch A Leffers E Albrecht-Beste LA. Konradsen Thrombin–antithrombin III complex and fibrin degradation products in plasma: surgery and postoperative deep venous thrombosis Thromb Res 59 1990 69 76
38. JA Hoek MT Nurmohamed JW ten Care HR Buller HC Knipscheer KJ. Hamelynck Thrombin–antithrombin III complexes in the prediction of deep vein thrombosis following total hip replacement Thromb Haemost 62 1989 1050 1052
39. MC Donaldson ET Matthews J Hadjimichael FR. Rickles Markers of thrombotic activity in arterial disease Arch Surg 122 1987 897 900
40. J Heinrich H Schulte R Schönfeld E Köhler G. Assmann Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain Thromb Haemost 73 1995 374 379
41. J Kienast SG Thompson C Raskino H Pelzer C Fechtrup H Ostermann Prothrombin activation fragment 1+2 and thrombin antithrombin III complexes in patients with angina pectoris: relation to the presence and severity of coronary atherosclerosis Thromb Haemost 70 1993 550 553
42. S Oshima H Yasue H Ogawa K Okumura K. Matsuyama Fibrinopeptide A is released into the coronary circulation after coronary spasm Circulation 82 1990 2222 2225
43. JB Kruskal PJ Commerford JJ Franks RE. Kirsch Fibrin and fibrinogen-related antigens in patients with stable and unstable coronary artery disease N Engl J Med 317 1987 1361 1365
44. PR Eisenberg LA Sherman K Schectman J Perez BE Sobel AS. Jaffe Fibrinopeptide A: a marker of acute coronary thrombosis Circulation 71 1985 912 918
45. UH Winkler S Koslowski C Oberhoff EM Schindler AE. Schindler Changes of the dynamic equilibrium of hemostasis associated with the use of low-dose oral contraceptives: a controlled study of cyproterone acetate containing oral contraceptives combined with either 35 or 50 mg ethinyl estradiol Adv Contracept 7 1991 273 284
46. P Broadhurst C Kelleher L Hughes JD Imeson EB. Raftery Fibrinogen, factor VII clotting activity and coronary artery disease severity Atherosclerosis 85 1990 169 173
47. F Haverkate M. Samama Familial dysfibrinogenemia and thrombophilia: report on a study of the SSC Subcommittee on Fibrinogen Thromb Haemost 73 1995 151 161
48. J Heinrich L Balleisen H Schulte G Assmann J. van de Loo Fibrinogen and factor VII in the prediction of coronary risk: results from the PROCAM study in healthy men Arterioscler Thromb 14 1994 54 59
49. CC. Kelleher Clinical aspects of the relationship between oral contraceptives and abnormalities of the hemostatic system: relation to the development of cardiovascular disease Am J Obstet Gynecol 163 1990 392 395
50. TW Meade V Ruddock Y Stirling R Chakrabarti GJ. Miller Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study Lancet 342 1993 1076 1079
51. TW Meade JA Cooper Y Stirling DJ Howarth V Ruddock GJ. Miller Factor VIII, blood group and the incidence of ischaemic heart disease Br J Haematol 88 1994 601 607
52. FR. Rosendaal Factor VIII and coronary heart disease Eur J Epidemiol 8 suppl 1 1992 71 75
53. V. Ruddock Factor-VII activity and ischaemic heart disease: fatal and non-fatal events QJM 87 1994 403 406
54. TW Wilson GA Kaplan J Kauhanen RD Cohen M Wu R Salonen Association between plasma fibrinogen concentration and five socioeconomic indices in the Kuopio Ischemic Heart Disease Risk Factor Study Am J Epidemiol 137 1993 292 300
55. L Bara V Nicaud L Tiret F Cambien MM. Samama Expression of a paternal history of premature myocardial infarction on fibrinogen, factor VIIC and PAI-1 in European offspring: the EARS study. European Atherosclerosis Research Study Group Thromb Haemost 71 1994 434 440
56. EM Bladbjerg P Marckmann B Sandstrom J. Jespersen Non-fasting factor VII coagulant activity (FVII:C) increased by high-fat diet Thromb Haemost 71 1994 755 758
57. GJ Miller JK Cruickshank LJ Ellis RL Thompson HC Wilkes Y Stirling Fat consumption and factor VII coagulant activity in middle-aged men: an association between a dietary and thrombogenic coronary risk factor Atherosclerosis 78 1989 19 24
58. E Moor A Silveira F van’t Hooft AM Suontaka P Eriksson M Blombäck Coagulation factor VII mass and activity in young men with myocardial infarction at a young age: role of plasma lipoproteins and factor VII genotype Arteriesclot Thromb Vase Biol 15 1995 655 664
59. P Bavenholm A Proudler A Silveira D Crook M Blombäck U de Faire Relationships of insulin and intact and split proinsulin to haemostatic function in young men with and without coronary artery disease Thromb Haemost 73 1995 568 575
60. S Vaisanen T Rankinen I Penttila R. Rauramaa Factor VII coagulant activity in relation to serum lipoproteins and dietary fat in middle-aged men Thromb Haemost 73 1995 435 438
61. CC. Kelleher Plasma fibrinogen and factor VII as risk factors for cardiovascular disease Eur J Epidemiol 8 suppl 1 1992 79 82
62. T Koster AD Blann E Briët JP Vandenbroucke FR. Rosendaal Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis Lancet 345 1995 152 155
63. T Koster FR Rosendaal PH Reitsma PA van der Velden E Briet JP. Vandenbroucke Factor VII and fibrinogen levels as risk factors for venous thrombosis: a case-control study of plasma levels and DNA polymorphisms-the Leiden Thrombophilia Study (LETS) Thomb Haemost 71 1994 719 722
64. R Kumar S Beguin HC. Hemker The influence of fibrinogen and fibrin on thrombin generation: evidence for feedback activation of the clotting system by clot bound thrombin Thromb Haemost 72 1994 713 721
65. MC Scrutton SB Ross-Murphy GM Bennett Y Stirling TW. Meade Changes in clot deformability: a possible explanation for the epidemiological association between plasma fibrinogen concentration and myocardial infarction Blood Coag Fibrinolysis 5 1994 719 723
66. JW Yarnell IA Baker PM Sweetnam D Bainton JR O’Brien PJ Whitehead Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell Collaborative Heart Disease Studies Circulation 83 1991 836 844
67. LI Mennen EG Schouten DE Grobbee C. Kluff Coagulation factor VII, dietary fat and blood lipids: a review Thromb Haemost 76 1996 492 499
68. G Plu-Bureau J Amiral L Guize PY. Scarabin Safety of combined oral contraceptive pills Lancet 347 1996 549 [letter]
69. B. Dahlbäck Physiological anticoagulation. Resistance to activated protein C and venous thromboembolism J Clin Invest 94 1994 923 927
70. JP Vandenbroucke T Koster E Briët PH Reitsma RM Bertina FR Rosendaal Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation Lancet 344 1994 1453 1457
71. RM Bertina PH Reitsma FR Rosendaal JP. Vandenbroucke Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis Thromb Haemost 74 1995 449 453
72. H de Ronde RM. Bertina Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria Thromb Haemost 72 1994 880 886
73. W Schramm LA. Heinemann Oral contraceptives and venous thromboembolism: acquired APC resistance? Br J Haematol 98 1997 491 492
74. J Rosing G Tans GA Nicolaes MC Thomassen R van Oerle PM van der Ploeg Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives Br J Haematol 97 1997 233 238